Compare AVLN & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | SCSC |
|---|---|---|
| Founded | N/A | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 1997 |
| Metric | AVLN | SCSC |
|---|---|---|
| Price | $33.84 | $58.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 175.5K | ★ 288.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.33 |
| EPS | N/A | ★ 3.64 |
| Revenue | N/A | ★ $3,846,260,000.00 |
| Revenue This Year | N/A | $2.60 |
| Revenue Next Year | N/A | $4.01 |
| P/E Ratio | ★ N/A | $15.65 |
| Revenue Growth | N/A | ★ 7.79 |
| 52 Week Low | $24.90 | $33.76 |
| 52 Week High | $40.17 | $66.78 |
| Indicator | AVLN | SCSC |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 48.84 |
| Support Level | $34.22 | $49.77 |
| Resistance Level | $40.08 | $59.46 |
| Average True Range (ATR) | 1.96 | 1.98 |
| MACD | -0.39 | -0.01 |
| Stochastic Oscillator | 9.89 | 32.97 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.